利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.059 秒)

    Methods of separating a corn fiber lipid fraction from corn fiber
    23.
    发明授权
    Methods of separating a corn fiber lipid fraction from corn fiber 失效
    从玉米纤维中分离玉米纤维脂质部分的方法

    公开(公告)号：US06589760B1

    公开(公告)日：2003-07-08

    申请号：US09501917

    申请日：2000-02-10

    申请人： Charles M. Buchanan ,  Norma L. Buchanan ,  John S. Debenham ,  Michael C. Shelton ,  Matthew D. Wood

    发明人： Charles M. Buchanan ,  Norma L. Buchanan ,  John S. Debenham ,  Michael C. Shelton ,  Matthew D. Wood

    IPC分类号： C12Q137

    CPC分类号： C13K1/08 ,  A23D9/007 ,  A23D9/02 ,  A23K10/37 ,  A23K20/147 ,  A23K20/163 ,  A23L7/107 ,  A23L7/115 ,  A23L29/262 ,  A23L33/11 ,  A23L33/115 ,  A23L33/24 ,  A23V2002/00 ,  C08B3/00 ,  C08B11/00 ,  C08B30/10 ,  C08B37/0057 ,  C08B37/006 ,  C11B1/025 ,  C11B1/10 ,  C13K1/02 ,  C13K13/00 ,  C13K13/002 ,  D21C5/00 ,  D21C5/005 ,  Y02P60/877 ,  A23V2250/602 ,  A23V2250/638 ,  A23V2250/626

    摘要： The invention provides a method of separating from corn fiber a lipid fraction having phytosterol esters and phytosterols where the method has the steps of: (a) heating an aqueous mixture of unground corn fiber; (b) contacting the mixture of step (a) with at least one enzyme suitable for digesting starch for a time and at a temperature suitable to provide a mixture of an essentially destarched corn fiber and a liquid comprising soluble carbohydrates; (c) contacting the mixture of step (a) or (b) with a protease enzyme to provide a proteolyzed corn fiber and a liquid; (d) separating the liquid of step (c) from the corn fiber to provide a destarched, proteolyzed corn fiber; and (e) extracting the destarched, proteolyzed corn fiber with at least one organic solvent. A corn fiber lipid fraction/organic solvent solution having phytosterol esters and phytosterols is provided. The invention also provides a corn fiber lipid fraction containing phytosterols and phytosterol esters obtained via solvent extraction of a proteolyzed corn fiber. The concentration of phytosterols and phytosterol esters in the lipid fraction is at least about 1.4 times greater than the concentration of phytosterols and phytosterol esters in the lipid fraction of a nonproteolyzed corn fiber.

    摘要翻译： 本发明提供了一种从玉米纤维中分离具有植物甾醇酯和植物甾醇的脂质部分的方法，其中该方法具有以下步骤：（a）加热未研磨的玉米纤维的水性混合物; （b）使步骤（a）的混合物与适合于消化淀粉的至少一种酶接触一段时间，并在适于提供基本上破裂的玉米纤维和包含可溶性碳水化合物的液体的混合物的温度下接触; （c）使步骤（a）或（b）的混合物与蛋白酶接触以提供蛋白水解的玉米纤维和液体; （d）将步骤（c）的液体与玉米纤维分离以提供破坏的蛋白水解的玉米纤维; 和（e）用至少一种有机溶剂萃取破坏了的，蛋白水解的玉米纤维。 提供了具有植物甾醇酯和植物甾醇的玉米纤维脂质部分/有机溶剂溶液。 本发明还提供了通过蛋白水解的玉米纤维的溶剂提取获得的含有植物甾醇和植物甾醇酯的玉米纤维脂质部分。 在脂质部分中植物甾醇和植物甾醇酯的浓度比非分解玉米纤维的脂质部分中的植物甾醇和植物甾醇酯的浓度高至少约1.4倍。

    Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
    24.
    发明授权
    Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators 失效
    取代的吡喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂

    公开(公告)号：US07999107B2

    公开(公告)日：2011-08-16

    申请号：US12009114

    申请日：2008-01-16

    申请人： John S. Debenham ,  Jeffrey J. Hale ,  Pei Huo ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Lin Yan

    发明人： John S. Debenham ,  Jeffrey J. Hale ,  Pei Huo ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Lin Yan

    IPC分类号： C07D491/052 ,  A61K31/436

    CPC分类号： C07D491/052 ,  C07D491/16 ,  C07D495/16

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物 脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，亨廷顿病运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

    Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators
    26.
    发明申请
    Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators 审中-公开
    取代的呋喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂

    公开(公告)号：US20080269279A1

    公开(公告)日：2008-10-30

    申请号：US12082013

    申请日：2008-04-07

    申请人： Matthew J. Clements ,  John S. Debenham ,  Jeffrey J. Hale ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Andrey V. Peresypkin ,  Roy Helmy

    发明人： Matthew J. Clements ,  John S. Debenham ,  Jeffrey J. Hale ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Andrey V. Peresypkin ,  Roy Helmy

    IPC分类号： A61K31/4355 ,  C07D471/04 ,  A61P25/00 ,  A61P3/04

    CPC分类号： C07D491/048

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物 脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

    Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
    27.
    发明申请
    Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators 失效
    取代的吡喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂

    公开(公告)号：US20080207666A1

    公开(公告)日：2008-08-28

    申请号：US12009114

    申请日：2008-01-16

    申请人： John S. Debenham ,  Jeffrey J. Hale ,  Pei Huo ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Lin Yan

    发明人： John S. Debenham ,  Jeffrey J. Hale ,  Pei Huo ,  Christina B. Madsen-Duggan ,  Thomas F. Walsh ,  Lin Yan

    IPC分类号： A61K31/527 ,  C07D471/10 ,  A61K31/4433 ,  C07D471/04 ,  A61P25/28

    CPC分类号： C07D491/052 ,  C07D491/16 ,  C07D495/16

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物 脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，亨廷顿病运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

    Substituted 2,3-diphenyl pyridines
    28.
    发明授权
    Substituted 2,3-diphenyl pyridines 失效
    取代的2,3-二苯基吡啶

    公开(公告)号：US07271266B2

    公开(公告)日：2007-09-18

    申请号：US10508043

    申请日：2003-03-24

    申请人： Paul E. Finke ,  Laura C. Meurer ,  John S. Debenham ,  Richard B. Toupence ,  Thomas F. Walsh

    发明人： Paul E. Finke ,  Laura C. Meurer ,  John S. Debenham ,  Richard B. Toupence ,  Thomas F. Walsh

    IPC分类号： C07D211/82 ,  C07D211/60

    CPC分类号： C07D213/79 ,  C04B35/632 ,  C07D213/65 ,  C07D213/80 ,  C07D213/81 ,  C07D213/82 ,  C07D213/85 ,  C07D213/86 ,  C07D213/87 ,  C07D401/12

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。